<DOC>
	<DOCNO>NCT00640835</DOCNO>
	<brief_summary>This study evaluate safety tolerability oral mucosa buprenorphine/naloxone film strip administer either sublingually buccally daily 12 week opioid dependent individual already stable regimen buprenorphine/naloxone .</brief_summary>
	<brief_title>Safety Tolerability Buprenorphine/Naloxone Film Strips</brief_title>
	<detailed_description>Buprenorphine naloxone soluble film develop alternative dosage form Suboxone ( buprenorphine naloxone ) sublingual tablet evaluate sublingual buccal administration . The soluble film dosage expect provide follow enhancement potential advantage current Suboxone ( buprenorphine naloxone ) product : - mitigation unintentional pediatric exposure provide child-resistant packaging unit dose format . - improvement subject convenience compliance ensure rapid disintegration . - protection diversion provide dosage form difficult subject remove sublingual buccal mucosa administration . This provide assurance caregiver dose actually take appropriately supervised setting . - provision unit dose product format hospital institutional use . - decreased product damage shipping compare Suboxone tablet .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>Subjects must : Be 18to65 year age , inclusive . Have diagnosis opioid dependence medical history accord DSMIVTR criterion . Be stable dose 4 32 mg ( express buprenorphine component ) daily Suboxone least 30 day . If female , negative pregnancy test screen agree use acceptable method birth control may include : Subjects must : Have participate experimental drug device study within last 30 day . If female , breast feeding lactating . Have medical condition opinion physician investigator would preclude subject complete study . Have clinically significant abnormal finding ( opinion Investigator ) oral cavity exam ( e.g. , active mouth ulcer ) . Have pierce tongue mouth within 30 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Opioid dependence</keyword>
</DOC>